{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:08:17Z","timestamp":1790298497948,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd004192.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T00:00:00Z","timestamp":1589846400000}}],"reference-count":214,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004192.pub4","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T22:03:16Z","timestamp":1589925796000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Dietary interventions for multiple sclerosis-related outcomes"],"prefix":"10.1002","volume":"2020","author":[{"given":"Natalie E","family":"Parks","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Neurology; Dalhousie University; Halifax Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin S","family":"Jackson-Tarlton","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Neurology; Dalhousie University; Halifax Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Vacchi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery; University of Milan-Bicocca; Monza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roah","family":"Merdad","sequence":"additional","affiliation":[{"name":"Department of Community Health and Epidemiology; Dalhousie University; Halifax Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley C","family":"Johnston","sequence":"additional","affiliation":[{"name":"Department of Nutrition; Texas A&M University; College Station Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,5,19]]},"reference":[{"issue":"6092","key":"10.1002\/14651858.CD004192.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1136\/bmj.2.6092.932-a","article-title":"Trial of polyunsaturated fatty acids in non-relapsing multiple sclerosis","volume":"2","author":"Bates","year":"1977","journal-title":"British Medical Journal"},{"issue":"6149","key":"10.1002\/14651858.CD004192.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1136\/bmj.2.6149.1390","article-title":"Polyunsaturated fatty acids in treatment of acute remitting multiple sclerosis","volume":"2","author":"Bates","year":"1978","journal-title":"British Medical Journal"},{"issue":"3","key":"10.1002\/14651858.CD004192.pub4-BIB0003|cit3","first-page":"118","article-title":"Trial of polyunsaturated fatty acids in multiple sclerosis [abstract]","volume":"147","author":"Shaw","year":"1978","journal-title":"Irish Journal of Medical Science"},{"issue":"1","key":"10.1002\/14651858.CD004192.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/jnnp.52.1.18","article-title":"A double-blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis","volume":"52","author":"Bates","year":"1989","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD004192.pub4-BIB0005|cit5","first-page":"277","article-title":"Results of a trial of N-3 polyunsaturated fatty acids in the treatment of multiple sclerosis [abstract]","volume":"157","author":"Bates","year":"1988","journal-title":"Irish Journal of Medical Science"},{"issue":"7","key":"10.1002\/14651858.CD004192.pub4-BIB0006|cit6","first-page":"435","article-title":"Impact of vitamin A supplementation on disease progression in patients with multiple sclerosis","volume":"18","author":"Bitarafan","year":"2015","journal-title":"Archives of Iranian Medicine"},{"issue":"1","key":"10.1002\/14651858.CD004192.pub4-BIB0007|cit7","first-page":"13","article-title":"Effect of Vitamin A supplementation on fatigue and depression in multiple sclerosis patients: A double-blind placebo-controlled clinical trial","volume":"15","author":"Bitarafan","year":"2016","journal-title":"Iranian Journal of Allergy, Asthma, and Immunology"},{"issue":"2","key":"10.1002\/14651858.CD004192.pub4-BIB0008|cit8","first-page":"94","article-title":"The effect of vitamin A supplementation on disease progression, cytokine levels and gene expression in multiple sclerotic patients: Study protocol for a randomized controlled trial","volume":"52","author":"Harrirchian","year":"2014","journal-title":"Acta Medica Iranica"},{"issue":"9","key":"10.1002\/14651858.CD004192.pub4-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1177\/1352458513517592","article-title":"Cranberry versus placebo in the prevention of urinary infections in multiple sclerosis: A multicenter, randomized, placebo-controlled, double-blind trial","volume":"20","author":"Gallien","year":"2014","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/1352458509360547","article-title":"Boosting endogenous neuroprotection in multiple sclerosis: the association of inosine and interferon beta in relapsing remitting multiple sclerosis (ASIIMS) trial","volume":"16","author":"Gonsette","year":"2010","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0011|cit11","first-page":"S44","article-title":"Association of interferon beta and inosine in relapsing-remitting multiple sclerosis (ASIIMS): a multi-centre, randomized, double-blind, placebo-controlled phase II (proof of concept) trial in 157 patients [abstract]","volume":"14","author":"Gonsette","year":"2008","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/DNND.S116949","article-title":"Randomized control trial evaluation of a modified paleolithic dietary intervention in the treatment of relapsing-remitting multiple sclerosis: A pilot study","volume":"7","author":"Irish","year":"2017","journal-title":"Degenerative Neurological and Neuromuscular Disease"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0013|cit13","first-page":"95","article-title":"Lipoic acid and multiple sclerosis: A randomized controlled clinical trial","volume":"10","author":"Khalili","year":"2012","journal-title":"Current Topics in Nutraceutical Research"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000356145","article-title":"Does lipoic acid consumption affect the cytokine profile in multiple sclerosis patients: A double-blind, placebo-controlled, randomized clinical trial","volume":"21","author":"Khalili","year":"2014","journal-title":"Neuroimmunomodulation"},{"issue":"1","key":"10.1002\/14651858.CD004192.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1179\/1476830513Y.0000000060","article-title":"Effect of lipoic acid consumption on oxidative stress among multiple sclerosis patients: A randomized controlled clinical trial","volume":"17","author":"Khalili","year":"2014","journal-title":"Nutritional Neuroscience"},{"issue":"S2","key":"10.1002\/14651858.CD004192.pub4-BIB0016|cit16","first-page":"825","article-title":"Effect of lipoic acid on oxidative stress in multiple sclerosis patients: A double blind randomised clinical trial [abstract]","volume":"23","author":"Seifar","year":"2016","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.clnu.2016.08.015","article-title":"Clinical and metabolic response to probiotic supplementation in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled trial","volume":"36","author":"Kouchaki","year":"2017","journal-title":"Clinical Nutrition"},{"issue":"S1","key":"10.1002\/14651858.CD004192.pub4-BIB0018|cit18","first-page":"524","article-title":"Green tea and energy metabolism in multiple sclerosis patients [abstract]","volume":"19","author":"M\u00e4hler","year":"2013","journal-title":"Multiple Sclerosis Journal"},{"issue":"3","key":"10.1002\/14651858.CD004192.pub4-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3945\/ajcn.113.075309","article-title":"Metabolic response to epigallocatechin-3-gallate in relapsing-remitting multiple sclerosis: A randomized clinical trial","volume":"101","author":"M\u00e4hler","year":"2015","journal-title":"American Journal of Clinical Nutrition"},{"issue":"1","key":"10.1002\/14651858.CD004192.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/19390210802328974","article-title":"Effect of creatine supplementation on muscle capacity in individuals with multiple sclerosis","volume":"5","author":"Malin","year":"2008","journal-title":"Journal of Dietary Supplements"},{"issue":"6","key":"10.1002\/14651858.CD004192.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1089\/acm.2008.0513","article-title":"The treatment of multiple sclerosis with inosine","volume":"15","author":"Markowitz","year":"2009","journal-title":"Journal of Alternative and Complementary Medicine"},{"issue":"5856","key":"10.1002\/14651858.CD004192.pub4-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/bmj.1.5856.765","article-title":"Double-blind trial of linoleate supplementation of the diet in multiple sclerosis","volume":"1","author":"Millar","year":"1973","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/ane.12333","article-title":"Associated inosine to interferon: Results of a clinical trial in multiple sclerosis","volume":"131","author":"Mu\u00f1oz Garc\u00eda","year":"2015","journal-title":"Acta Neurologica Scandanavia"},{"issue":"5","key":"10.1002\/14651858.CD004192.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1024\/0300-9831\/a000170","article-title":"Riboflavin supplementation to patients with multiple sclerosis does not improve disability status nor is riboflavin supplementation correlated to homocysteine","volume":"83","author":"Naghashpour","year":"2013","journal-title":"International Journal of Vitamin and Nutrition Research"},{"issue":"S1","key":"10.1002\/14651858.CD004192.pub4-BIB0025|cit25","first-page":"S437","article-title":"A double-blind, randomized, versus-placebo study of palmitoylethanolamide in subjects with relapsing remitting multiple sclerosis: Preliminary results [abstract]","volume":"261","author":"Montella","year":"2014","journal-title":"Journal of Neurology"},{"issue":"S1","key":"10.1002\/14651858.CD004192.pub4-BIB0026|cit26","first-page":"114","article-title":"A double-blind, randomized, versus-placebo study of palmitoylethanolamide in relapsing-remitting multiple sclerosis [abstract]","volume":"20","author":"Orefice","year":"2014","journal-title":"Multiple Sclerosis Journal"},{"issue":"2","key":"10.1002\/14651858.CD004192.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s13311-016-0420-z","article-title":"Oral palmitoylethanolamide treatment is associated with reduced cutaneous adverse effects of interferon-\u03b21a and circulating proinflammatory cytokines in relapsing-remitting multiple sclerosis","volume":"13","author":"Orefice","year":"2016","journal-title":"Neurotherapeutics"},{"issue":"S4","key":"10.1002\/14651858.CD004192.pub4-BIB0028|cit28","first-page":"473","article-title":"A novel oral medical nutrition formula (PLP10) for the treatment of relapsing-remitting multiple sclerosis: A randomised, double-blind, placebo-controlled proof-of-concept clinical trial [abstract]","volume":"18","author":"Pantzaris","year":"2012","journal-title":"Multiple Sclerosis Journal"},{"issue":"4","key":"10.1002\/14651858.CD004192.pub4-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"e002170","DOI":"10.1136\/bmjopen-2012-002170","article-title":"A novel oral nutraceutical formula of omega-3 and omega-6 fatty acids with vitamins (PLP10) in relapsing remitting multiple sclerosis: a randomised, double-blind, placebo-controlled proof-of-concept clinical trial","volume":"3","author":"Pantzaris","year":"2013","journal-title":"BMJ Open"},{"issue":"S11","key":"10.1002\/14651858.CD004192.pub4-BIB0030|cit30","first-page":"323","article-title":"Omega-3, omega-6 PUFA and gamma-tocopherol in multiple sclerosis: PLP10 intervention efficacy and red blood cells' membrane lipids composition [abstract]","volume":"21","author":"Patrikios","year":"2015","journal-title":"Multiple Sclerosis Journal"},{"issue":"1","key":"10.1002\/14651858.CD004192.pub4-BIB0031|cit31","first-page":"266","article-title":"Oral nutraceutical formula (PLP10) for the treatment of relapsing remitting multiple sclerosis: double-blind, randomized clinical trial [abstract]","volume":"7","author":"Patrikios","year":"2012","journal-title":"Clinical Nutrition"},{"issue":"7917","key":"10.1002\/14651858.CD004192.pub4-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0140-6736(75)93189-X","article-title":"Letter: Linoleic acid in multiple sclerosis","volume":"1","author":"Paty","year":"1975","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD004192.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1600-0404.1978.tb02859.x","article-title":"Linoleic acid in multiple sclerosis: Failure to show any therapeutic benefit","volume":"58","author":"Paty","year":"1978","journal-title":"Acta Neurologica Scandinavica"},{"issue":"11","key":"10.1002\/14651858.CD004192.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1001\/archneur.1983.04050100033011","article-title":"Double-blind trial of linoleic acid in multiple sclerosis","volume":"40","author":"Paty","year":"1983","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"709493","DOI":"10.1155\/2013\/709493","article-title":"Efficacy of fish oil on serum of TNF \u03b1 , IL-1 \u03b2, and IL-6 oxidative stress markers in multiple sclerosis treated with interferon beta-1b","volume":"2013","author":"Ramirez-Ramirez","year":"2013","journal-title":"Oxidative Medicine and Cellular Longevity"},{"issue":"12","key":"10.1002\/14651858.CD004192.pub4-BIB0036|cit36","first-page":"1836","article-title":"Effect of fish oil on cytokines, oxidative stress markers and progression disability in multiple sclerosis [abstract]","volume":"18","author":"Ramirez-Ramirez","year":"2012","journal-title":"Multiple Sclerosis Journal"},{"issue":"2","key":"10.1002\/14651858.CD004192.pub4-BIB0037|cit37","first-page":"145","article-title":"Effect of fish oil on glutathione redox system in multiple sclerosis","volume":"5","author":"Sorto-Gomez","year":"2016","journal-title":"American Journal of Neurodegenerative Disease"},{"issue":"5","key":"10.1002\/14651858.CD004192.pub4-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ctim.2015.07.003","article-title":"Alteration of delta-6-desaturase (FADS2), secretory phospholipase-A2 (sPLA2) enzymes by Hot-nature diet with co-supplemented hemp seed, evening primrose oils intervention in multiple sclerosis patients","volume":"23","author":"Rezapour-Firouzi","year":"2015","journal-title":"Complementary Therapies in Medicine"},{"issue":"6","key":"10.1002\/14651858.CD004192.pub4-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.ctim.2014.10.004","article-title":"Activity of liver enzymes in multiple sclerosis patients with Hot-nature diet and co-supplemented hemp seed, evening primrose oils intervention","volume":"22","author":"Rezapour-Firouzi","year":"2014","journal-title":"Complementary Therapies in Medicine"},{"issue":"6","key":"10.1002\/14651858.CD004192.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"519","DOI":"10.4314\/ajtcam.v10i6.22","article-title":"Erythrocyte membrane fatty acids in multiple sclerosis patients and hot-nature dietary intervention with co-supplemented hemp-seed and evening-primrose oils","volume":"10","author":"Rezapour-Firouzi","year":"2013","journal-title":"African Journal of Traditional, Complementary, and Alternative Medicine"},{"issue":"5","key":"10.1002\/14651858.CD004192.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ctim.2013.06.006","article-title":"Immunomodulatory and therapeutic effects of hot-nature diet and co-supplemented hemp seed, evening primrose oils intervention in multiple sclerosis patients","volume":"21","author":"Rezapour-Firouzi","year":"2013","journal-title":"Complementary Therapies in Medicine"},{"issue":"4","key":"10.1002\/14651858.CD004192.pub4-BIB0042|cit42","first-page":"2891","article-title":"Regulation of lipid-dependent membrane enzymes by hot nature diet with co-supplemented hemp seed, evening primrose oils intervention in multiple sclerosis patients","volume":"7","author":"Rezapour-Firouzi","year":"2013","journal-title":"Journal of Pure and Applied Microbiology"},{"issue":"3","key":"10.1002\/14651858.CD004192.pub4-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1179\/1476830515Y.0000000002","article-title":"Coenzyme Q10 as a treatment for fatigue and depression in multiple sclerosis patients: A double blind randomized clinical trial","volume":"19","author":"Sanoobar","year":"2016","journal-title":"Nutritional Neuroscience"},{"issue":"11","key":"10.1002\/14651858.CD004192.pub4-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3109\/00207454.2013.801844","article-title":"Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with relapsing-remitting multiple sclerosis","volume":"123","author":"Sanoobar","year":"2013","journal-title":"International Journal of Neuroscience"},{"issue":"4","key":"10.1002\/14651858.CD004192.pub4-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1179\/1476830513Y.0000000106","article-title":"Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: A double blind, placebo, controlled randomized clinical trial","volume":"18","author":"Sanoobar","year":"2015","journal-title":"Nutritional Neuroscience"},{"issue":"S11","key":"10.1002\/14651858.CD004192.pub4-BIB0046|cit46","first-page":"330","article-title":"A double blind clinical trial of the effect of coenzyme Q10 on oxidative stress, depression and fatigue in multiple sclerosis patients [abstract]","volume":"21","author":"Seifar","year":"2015","journal-title":"Multiple Sclerosis Journal"},{"issue":"1","key":"10.1002\/14651858.CD004192.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"e0147195","DOI":"10.1371\/journal.pone.0147195","article-title":"Omega-3 fatty acids for depression in multiple sclerosis: A randomized pilot study","volume":"11","author":"Shinto","year":"2016","journal-title":"PLoS One"},{"issue":"S2","key":"10.1002\/14651858.CD004192.pub4-BIB0048|cit48","first-page":"A295","article-title":"Omega-3 fatty acids as an adjunct therapy for depression in multiple sclerosis: A randomized, double-blind placebo-controlled pilot trial [abstract]","volume":"74","author":"Shinto","year":"2010","journal-title":"Neurology"},{"issue":"1-2","key":"10.1002\/14651858.CD004192.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2003.11.005","article-title":"Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: Results of a pilot, randomised, double-blind, crossover trial","volume":"218","author":"Tomassini","year":"2004","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jneuroim.2015.09.008","article-title":"Body mass index influence interferon-beta treatment response in multiple sclerosis","volume":"288","author":"Kvistad","year":"2015","journal-title":"Journal of Neuroimmunology"},{"issue":"S11","key":"10.1002\/14651858.CD004192.pub4-BIB0051|cit51","first-page":"165","article-title":"Body mass index influence disease activity and interferon-beta treatment response in multiple sclerosis [abstract]","volume":"21","author":"Kvistad","year":"2015","journal-title":"Multiple Sclerosis Journal"},{"issue":"S2","key":"10.1002\/14651858.CD004192.pub4-BIB0052|cit52","first-page":"49","article-title":"Omega-3 fatty acids treatment in relapsing-remitting multiple sclerosis [abstract]","volume":"18","author":"Torkildsen","year":"2011","journal-title":"European Journal of Neurology"},{"issue":"S1","key":"10.1002\/14651858.CD004192.pub4-BIB0053|cit53","first-page":"412","article-title":"Effect of omega-3 fatty acid treatment in multiple sclerosis (OFAMS study): Results from a randomised, double-blind, placebo-controlled trial [abstract]","volume":"17","author":"Torkildsen","year":"2011","journal-title":"Multiple Sclerosis Journal"},{"issue":"S1","key":"10.1002\/14651858.CD004192.pub4-BIB0054|cit54","first-page":"15","article-title":"Alpha-linolenic acid (ALA) serum levels are associated with reduced MRI activity in a prospective cohort of MS patients [abstract]","volume":"23","author":"Torkildsen","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"8","key":"10.1002\/14651858.CD004192.pub4-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1001\/archneurol.2012.283","article-title":"Omega-3 fatty acid treatment in multiple sclerosis (OFAMS Study): A randomized, double-blind, placebo-controlled trial","volume":"69","author":"Torkildsen","year":"2012","journal-title":"Archives of Neurology"},{"issue":"S3","key":"10.1002\/14651858.CD004192.pub4-BIB0056|cit56","first-page":"35","article-title":"MD1003 in progressive multiple sclerosis: 24-month brain MRI results of the MS-SPI trial [abstract]","volume":"23","author":"Arnold","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"S3","key":"10.1002\/14651858.CD004192.pub4-BIB0057|cit57","first-page":"402","article-title":"Effect of MD1003 (high-dose biotin) in spinal progressive multiple sclerosis (MS-SPI): Subgroup analyses [abstract]","volume":"23","author":"Laplaud","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"13","key":"10.1002\/14651858.CD004192.pub4-BIB0058|cit58","first-page":"NP12","article-title":"Pharmaceutical-grade high-dose biotin improves outcome in non-active progressive multiple sclerosis: Phase 3 placebo-controlled results [abstract]","volume":"23","author":"Lasser","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"S3","key":"10.1002\/14651858.CD004192.pub4-BIB0059|cit59","first-page":"938","article-title":"Effect of MD1003 (high-dose biotin) in spinal progressive multiple sclerosis (MS-SPI): EDSS sub-scores [abstract]","volume":"23","author":"Papeix","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"3","key":"10.1002\/14651858.CD004192.pub4-BIB0060|cit60","first-page":"825","article-title":"High dose biotin for not-active progressive multiple sclerosis [abstract]","volume":"14","author":"Sedel","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"S14","key":"10.1002\/14651858.CD004192.pub4-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"PL2.002","DOI":"10.1212\/WNL.84.14_supplement.PL2.002","article-title":"Effect of MD1003 (high doses of biotin) in progressive multiple sclerosis: Results of a pivotal phase III randomized double blind placebo controlled study [abstract]","volume":"84","author":"Tourbah","year":"2015","journal-title":"Neurology"},{"issue":"S2","key":"10.1002\/14651858.CD004192.pub4-BIB0062|cit62","first-page":"70","article-title":"High doses of biotin in progressive multiple sclerosis: Extension phase results of the MS-SPI trial [abstract]","volume":"23","author":"Tourbah","year":"2016","journal-title":"European Journal of Neurology"},{"issue":"S11","key":"10.1002\/14651858.CD004192.pub4-BIB0063|cit63","first-page":"785","article-title":"MD1003 (high doses of biotin) in progressive multiple sclerosis: Subgroup analyses of the MS-SPI trial [abstract]","volume":"21","author":"Tourbah","year":"2015","journal-title":"Multiple Sclerosis Journal"},{"issue":"13","key":"10.1002\/14651858.CD004192.pub4-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1177\/1352458516667568","article-title":"MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study","volume":"22","author":"Tourbah","year":"2016","journal-title":"Multiple Sclerosis Journal"},{"issue":"S1","key":"10.1002\/14651858.CD004192.pub4-BIB0065|cit65","first-page":"49","article-title":"Effect of MD1003 (high doses of biotin) in progressive multiple sclerosis: results of a pivotal phase III randomised double-blind placebo controlled study [abstract]","volume":"22","author":"Tourbah","year":"2015","journal-title":"European Journal of Neurology"},{"issue":"S3","key":"10.1002\/14651858.CD004192.pub4-BIB0066|cit66","first-page":"401","article-title":"Effect of MD1003 (high-dose biotin) for the treatment of progressive MS: 36-month follow-up data [abstract]","volume":"23","author":"Vukusic","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"7","key":"10.1002\/14651858.CD004192.pub4-BIB0067|cit67","first-page":"A461","article-title":"A randomized study of low-fat diet with omega-3 fatty acid supplementation in patients with relapsing-remitting multiple sclerosis (RRMS) [abstract]","volume":"58","author":"Weinstock-Guttman","year":"2002","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD004192.pub4-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.plefa.2005.05.024","article-title":"Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients","volume":"73","author":"Weinstock-Guttman","year":"2005","journal-title":"Prostaglandins, Leukotrienes, and Essential Fatty Acids"},{"issue":"2","key":"10.1002\/14651858.CD004192.pub4-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1191\/1352458505ms1143oa","article-title":"Lipoic acid in multiple sclerosis: A pilot study","volume":"11","author":"Yadav","year":"2005","journal-title":"Multiple Sclerosis"},{"issue":"S1","key":"10.1002\/14651858.CD004192.pub4-BIB0070|cit70","first-page":"91","article-title":"Effects of a very low fat, plant-food based diet on fatigue in multiple sclerosis: Report of a pilot trial [abstract]","volume":"20","author":"Yadav","year":"2014","journal-title":"Multiple Sclerosis Journal"},{"issue":"S10","key":"10.1002\/14651858.CD004192.pub4-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"P6.152","DOI":"10.1212\/WNL.82.10_supplement.P6.152","article-title":"Effects of a low fat plant based diet in multiple sclerosis (MS): results of a 1-year long randomized controlled (RC) study [abstract]","volume":"82","author":"Yadav","year":"2014","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.msard.2016.07.001","article-title":"Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial","volume":"9","author":"Yadav","year":"2016","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.clineuro.2017.10.004","article-title":"Evaluating the effect of adding Fish oil to Fingolimod on TNF-alpha, IL1beta, IL6, and IFN-gamma in patients with relapsing-remitting multiple sclerosis: A double-blind randomized placebo-controlled trial","volume":"163","author":"Zandi-Esfahan","year":"2017","journal-title":"Clinical Neurology and Neurosurgery"},{"issue":"2","key":"10.1002\/14651858.CD004192.pub4-BIB0074|cit74","first-page":"44","article-title":"Possibilities of treatment of multiple sclerosis exacerbations without corticosteroids: A role of metabolic and antioxidant therapy","volume":"111","author":"Bisaga","year":"2011","journal-title":"Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova"},{"issue":"2","key":"10.1002\/14651858.CD004192.pub4-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11055-011-9544-0","article-title":"Treatment of exacerbations of multiple sclerosis without the use of corticosteroids: the role of metabolic and antioxidant therapy","volume":"42","author":"Bisaga","year":"2012","journal-title":"Neuroscience and Behavioral Physiology"},{"issue":"2","key":"10.1002\/14651858.CD004192.pub4-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s12031-013-0090-9","article-title":"Impact of vitamin A supplementation on RAR gene expression in multiple sclerosis patients","volume":"51","author":"Bitarafan","year":"2013","journal-title":"Journal of Molecular Neuroscience"},{"issue":"S20","key":"10.1002\/14651858.CD004192.pub4-BIB0077|cit77","first-page":"S117","article-title":"The pharmacokinetics of lipoic acid at baseline and 48 weeks in secondary progressive multiple sclerosis patients","volume":"80","author":"Bittner","year":"2016","journal-title":"Annals of Neurology"},{"issue":"8","key":"10.1002\/14651858.CD004192.pub4-BIB0078|cit78","first-page":"225","article-title":"Unsaturated fatty acids in the immunology and therapy of multiple sclerosis","volume":"37","author":"Cendrowski","year":"1982","journal-title":"Polski Tygodnik Lekarski"},{"issue":"S1","key":"10.1002\/14651858.CD004192.pub4-BIB0079|cit79","first-page":"69","article-title":"Intermittent fasting in experimental autoimmune encephalomyelitis and multiple sclerosis","volume":"23","author":"Cignarella","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"S3","key":"10.1002\/14651858.CD004192.pub4-BIB0080|cit80","first-page":"823","article-title":"The effect of high flavonoid cocoa on fatigue in people with multiple sclerosis","volume":"22","author":"Coe","year":"2016","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.clnesp.2017.07.002","article-title":"Flavonoid rich dark cocoa may improve fatigue in people with multiple sclerosis, yet has no effect on glycaemic response: An exploratory trial","volume":"21","author":"Coe","year":"2017","journal-title":"Clinical Nutrition ESPEN"},{"issue":"8230","key":"10.1002\/14651858.CD004192.pub4-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0140-6736(81)92315-1","article-title":"Linoleic acid and multiple sclerosis","volume":"1","author":"Dworkin","year":"1981","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD004192.pub4-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1212\/WNL.34.11.1441","article-title":"Linoleic acid and multiple sclerosis: A reanalysis of three double-blind trials","volume":"34","author":"Dworkin","year":"1984","journal-title":"Neurology"},{"issue":"S1","key":"10.1002\/14651858.CD004192.pub4-BIB0084|cit84","first-page":"301","article-title":"Study of the effect of lipoic acid consumption on cytokine profile: A double-blind randomized clinical trial","volume":"67","author":"Eghtesadi","year":"2015","journal-title":"Annals of Nutrition and Metabolism"},{"issue":"6160","key":"10.1002\/14651858.CD004192.pub4-BIB0085|cit85","first-page":"411","article-title":"Polyunsaturated fatty acids and colchicine in multiple sclerosis","volume":"1","author":"Field","year":"1979","journal-title":"British Medical Journal"},{"issue":"S3","key":"10.1002\/14651858.CD004192.pub4-BIB0086|cit86","first-page":"664","article-title":"Calorie restriction diets and changes in the metabolome in people with multiple sclerosis","volume":"23","author":"Fitzgerald","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"S3","key":"10.1002\/14651858.CD004192.pub4-BIB0087|cit87","first-page":"761","article-title":"Concomitant changes in weight and in sleep quality among people with multiple sclerosis","volume":"23","author":"Fitzgerald","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"S16","key":"10.1002\/14651858.CD004192.pub4-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"P3.390","DOI":"10.1212\/WNL.88.16_supplement.P3.390","article-title":"Effects of intermittent calorie restriction on weight, fat mass, lean mass, visceral adipose tissue: Results from a pilot controlled-feeding study in multiple sclerosis patients","volume":"88","author":"Fitzgerald","year":"2017","journal-title":"Neurology"},{"issue":"S21","key":"10.1002\/14651858.CD004192.pub4-BIB0089|cit89","first-page":"S191","article-title":"Calorie restriction diets and changes in the metabolome in people with multiple","volume":"82","author":"Fitzgerald","year":"2017","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0090|cit90","first-page":"S208","article-title":"Evaluation of efficacy of an add-on therapy with cianocobalamine (Vitamin B12) plus calcium levofolinate in relapsing-remitting multiple sclerosis patients already in treatment with interferon beta over a period of 24 months for a better longterm outcome (ADVANCE)","volume":"17","author":"Gasperini","year":"2011","journal-title":"Multiple Sclerosis Journal"},{"issue":"S1","key":"10.1002\/14651858.CD004192.pub4-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1017\/S0007114507833010","article-title":"Polyunsaturated fatty acids in the pathogenesis and treatment of multiple sclerosis","volume":"98","author":"Harbige","year":"2007","journal-title":"British Journal of Nutrition"},{"issue":"9","key":"10.1002\/14651858.CD004192.pub4-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"e75021","DOI":"10.1371\/journal.pone.0075021","article-title":"Inflammation markers in multiple sclerosis: CXCL16 reflects and may also predict disease activity","volume":"8","author":"Holmoy","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1002\/14651858.CD004192.pub4-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"294","DOI":"10.4103\/0976-3147.102609","article-title":"The effect of vitamin A supplementation on stimulated T-cell proliferation with myelin oligodendrocyte glycoprotein in patients with multiple sclerosis","volume":"3","author":"Jafarirad","year":"2012","journal-title":"Journal of Neurosciences in Rural Practice"},{"issue":"3","key":"10.1002\/14651858.CD004192.pub4-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"194","DOI":"10.5812\/ircmj.3480","article-title":"The effect of vitamin A supplementation on biochemical parameters in multiple sclerosis patients","volume":"15","author":"Jafarirad","year":"2013","journal-title":"Iranian Red Crescent Medical Journal"},{"issue":"8","key":"10.1002\/14651858.CD004192.pub4-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/jn\/nxy116","article-title":"High-dose \u03c9-3 fatty acid plus vitamin D3 supplementation affects clinical symptoms and metabolic status of patients with multiple sclerosis: a randomized controlled clinical trial","volume":"148","author":"Kouchaki","year":"2018","journal-title":"Journal of Nutrition"},{"issue":"8","key":"10.1002\/14651858.CD004192.pub4-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0003-9993(03)00262-4","article-title":"Influence of creatine monohydrate ingestion on muscle metabolites and intense exercise capacity in individuals with multiple sclerosis","volume":"84","author":"Lambert","year":"2003","journal-title":"Archives of Physical Medicine and Rehabilitation"},{"issue":"1","key":"10.1002\/14651858.CD004192.pub4-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.clnu.2016.12.029","article-title":"Intake of tryptophan-enriched whey protein acutely enhances recall of positive loaded words in patients with multiple sclerosis","volume":"37","author":"Lieben","year":"2018","journal-title":"Clinical Nutrition"},{"issue":"5","key":"10.1002\/14651858.CD004192.pub4-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0306-9877(02)00261-X","article-title":"Treatment of multiple sclerosis with lofepramine, L-phenylalanine and vitamin B12: Mechanism of action and clinical importance: roles of the locus coeruleus and central noradrenergic systems","volume":"59","author":"Loder","year":"2002","journal-title":"Medical Hypotheses"},{"issue":"5","key":"10.1002\/14651858.CD004192.pub4-BIB0099|cit99","first-page":"S12","article-title":"D-mannose, cranberry and Vitamin C are effective in preventing urinary tract infections in multiple sclerosis subjects","volume":"18","author":"Lopes De Carvalho","year":"2012","journal-title":"Multiple Sclerosis Journal"},{"issue":"1-2","key":"10.1002\/14651858.CD004192.pub4-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jns.2015.08.006","article-title":"Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: Phase I single group and phase II randomized placebo-controlled studies","volume":"358","author":"Lovera","year":"2015","journal-title":"Journal of Neurological Sciences"},{"issue":"6","key":"10.1002\/14651858.CD004192.pub4-BIB0101|cit101","first-page":"2229","article-title":"Effects of a low-fat diet with antioxidant supplementation on biochemical markers of multiple sclerosis long-term care residents","volume":"28","author":"Mauriz","year":"2013","journal-title":"Nutricion Hospitalaria"},{"issue":"2","key":"10.1002\/14651858.CD004192.pub4-BIB0102|cit102","first-page":"764","article-title":"Effects of dietary supplementation with lemon verbena extracts on serum inflammatory markers of multiple sclerosis patients","volume":"31","author":"Mauriz","year":"2014","journal-title":"Nutricion Hospitalaria"},{"issue":"5869","key":"10.1002\/14651858.CD004192.pub4-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/bmj.2.5869.777-b","article-title":"Unsaturated fatty acids in multiple sclerosis","volume":"2","author":"Mertin","year":"1973","journal-title":"British Medical Journal"},{"issue":"7992","key":"10.1002\/14651858.CD004192.pub4-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0140-6736(76)90934-X","article-title":"Effect of gamma-linolenate in multiple sclerosis","volume":"2","author":"Meyer-Rienecker","year":"1976","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD004192.pub4-BIB0105|cit105","first-page":"153","article-title":"Preliminary-results of double-blind linoleic-acid treatment trials in multiple-sclerosis carried out in Belfast, Newcastle-Upon-Tyne and London, Ontario","volume":"153","author":"Millar","year":"1984","journal-title":"Irish Journal of Medical Science"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"175628641881907","DOI":"10.1177\/1756286418819074","article-title":"Coenzyme Q10 supplementation reduces peripheral oxidative stress and inflammation in interferon-\u03b21a-treated multiple sclerosis","volume":"12","author":"Moccia","year":"2019","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"3","key":"10.1002\/14651858.CD004192.pub4-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s12031-013-0058-9","article-title":"The effect of vitamin A supplementation on retinoic acid-related orphan receptor \u03b3t (ROR\u03b3t) and interleukin-17 (IL-17) gene expression in Avonex-treated multiple sclerotic patients","volume":"51","author":"Mohammadzadeh Honarvar","year":"2013","journal-title":"Journal of Molecular Neuroscience"},{"issue":"3","key":"10.1002\/14651858.CD004192.pub4-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s12031-016-0747-2","article-title":"Retinyl palmitate supplementation modulates T-bet and interferon gamma gene expression in multiple sclerosis patients","volume":"59","author":"Mohammadzadeh Honarvar","year":"2016","journal-title":"Journal of Molecular Neuroscience"},{"issue":"3","key":"10.1002\/14651858.CD004192.pub4-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s12031-015-0549-y","article-title":"The effect of vitamin A supplementation on FoxP3 and TGF-\u03b2 gene expression in avonex-treated multiple sclerosis patients","volume":"56","author":"Saboor-Yaraghi","year":"2015","journal-title":"Journal of Molecular Neuroscience"},{"issue":"3","key":"10.1002\/14651858.CD004192.pub4-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.pharep.2015.01.002","article-title":"Zinc sulphate: A reasonable choice for depression management in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial","volume":"67","author":"Salari","year":"2015","journal-title":"Pharmacological Reports"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.3389\/fimmu.2017.01391","article-title":"Immunological and clinical effect of diet modulation of the gut microbiome in multiple sclerosis patients: A pilot study","volume":"8","author":"Saresella","year":"2017","journal-title":"Frontiers in Immunology"},{"issue":"3","key":"10.1002\/14651858.CD004192.pub4-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1207\/s15327655jchn0103_5","article-title":"Efficacy of cranberry juice and ascorbic acid in acidifying the urine in multiple sclerosis subjects","volume":"1","author":"Schultz","year":"1984","journal-title":"Journal of Community Health Nursing"},{"issue":"5","key":"10.1002\/14651858.CD004192.pub4-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1089\/acm.2007.0757","article-title":"A randomized pilot study of naturopathic medicine in multiple sclerosis","volume":"14","author":"Shinto","year":"2008","journal-title":"Journal of Alternative and Complementary Medicine"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0114|cit114","first-page":"1053","article-title":"Dietary supplementation with Efamol and multiple sclerosis","volume":"98","author":"Simpson","year":"1985","journal-title":"New Zealand Medical Journal"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0115|cit115","first-page":"267","article-title":"Trials in the treatment of multiple sclerosis with diabetol associated with diets poor in carbohydrates","volume":"9","author":"Skakonik","year":"1963","journal-title":"Annales Academiae Medicae Stetinensis"},{"issue":"5","key":"10.1002\/14651858.CD004192.pub4-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/jhh.2009.83","article-title":"Modulation of serum uric acid levels by inosine in patients with multiple sclerosis does not affect blood pressure","volume":"24","author":"Spitsin","year":"2010","journal-title":"Journal of Human Hypertension"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/00005053-196012000-00002","article-title":"Multiple sclerosis: assessment of treatment with a modified low-fat diet","volume":"131","author":"Swank","year":"1960","journal-title":"Journal of Nervous and Mental Disease"},{"issue":"8706","key":"10.1002\/14651858.CD004192.pub4-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0140-6736(90)91533-G","article-title":"Effect of low saturated fat diet in early and late cases of multiple sclerosis","volume":"336","author":"Swank","year":"1990","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD004192.pub4-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0899-9007(02)00851-1","article-title":"Review of MS patient survival on a Swank low saturated fat diet","volume":"19","author":"Swank","year":"2003","journal-title":"Nutrition"},{"issue":"6","key":"10.1002\/14651858.CD004192.pub4-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/ajcn\/48.6.1387","article-title":"Multiple sclerosis: the lipid relationship","volume":"48","author":"Swank","year":"1988","journal-title":"American Journal of Clinical Nutrition"},{"issue":"5","key":"10.1002\/14651858.CD004192.pub4-BIB0121|cit121","first-page":"368","article-title":"Multiple sclerosis: Fat-oil relationship","volume":"7","author":"Swank","year":"1991","journal-title":"Nutrition"},{"issue":"5","key":"10.1002\/14651858.CD004192.pub4-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1001\/archneur.1970.00480290080009","article-title":"Multiple sclerosis: Twenty years on low fat diet","volume":"23","author":"Swank","year":"1970","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0002-8223(21)18155-6","article-title":"Treatment of multiple sclerosis with a low-fat diet","volume":"36","author":"Swank","year":"1960","journal-title":"Journal of the American Dietetic Association"},{"issue":"1","key":"10.1002\/14651858.CD004192.pub4-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1001\/archneurpsyc.1953.02320250097011","article-title":"Treatment of multiple sclerosis with low-fat diet","volume":"69","author":"Swank","year":"1953","journal-title":"AMA Archives of Neurology and Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD004192.pub4-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"812","DOI":"10.7326\/0003-4819-45-5-812","article-title":"Treatment of multiple sclerosis with low-fat diet: Result of seven years' experience","volume":"45","author":"Swank","year":"1956","journal-title":"Annals of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD004192.pub4-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/archneurpsyc.1955.02330120035004","article-title":"Treatment of multiple sclerosis with low-fat diet; results of five and one-half years' experience","volume":"73","author":"Swank","year":"1955","journal-title":"AMA Archives of Neurology and Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD004192.pub4-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00000441-195201000-00005","article-title":"The influence of low-fat diet on blood lipid levels in health and in multiple sclerosis","volume":"223","author":"Wilmot","year":"1952","journal-title":"American Journal of the Medical Sciences"},{"issue":"8","key":"10.1002\/14651858.CD004192.pub4-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1080\/07315724.2017.1347074","article-title":"The effects of probiotic supplementation on gene expression related to inflammation, insulin, and lipids in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled trial","volume":"36","author":"Tamtaji","year":"2017","journal-title":"Journal of the American College of Nutrition"},{"issue":"10","key":"10.1002\/14651858.CD004192.pub4-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2298\/VSP0610879T","article-title":"Therapeutic value of serum uric acid levels increasing in the treatment of multiple sclerosis","volume":"63","author":"Toncev","year":"2006","journal-title":"Vojnosanitetski Pregled"},{"issue":"S3","key":"10.1002\/14651858.CD004192.pub4-BIB0130|cit130","first-page":"374","article-title":"Effects of high-and low-fat meals on the pharmacokinetics of ozanimod, a novel sphingosine 1-phosphate receptor modulator","volume":"22","author":"Tran","year":"2016","journal-title":"Multiple Sclerosis Journal"},{"issue":"6","key":"10.1002\/14651858.CD004192.pub4-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/cpdd.409","article-title":"Effects of high- and low-fat meals on the pharmacokinetics of ozanimod, a novel sphingosine-1-phosphate receptor modulator","volume":"7","author":"Tran","year":"2018","journal-title":"Clinical Pharmacology in Drug Development"},{"issue":"2-3","key":"10.1002\/14651858.CD004192.pub4-BIB0132|cit132","first-page":"121","article-title":"Iron and the folate-vitamin B12-methylation pathway in multiple sclerosis","volume":"21","author":"Rensburg","year":"2006","journal-title":"Metabolic Brain Disease"},{"issue":"3","key":"10.1002\/14651858.CD004192.pub4-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1136\/jnnp.73.3.246","article-title":"A randomised placebo controlled exploratory study of vitamin B12, lofepramine, and L-phenylalanine (the \"Cari Loder regime\") in the treatment of multiple sclerosis","volume":"73","author":"Wade","year":"2002","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"S11","key":"10.1002\/14651858.CD004192.pub4-BIB0134|cit134","first-page":"794","article-title":"Ketogenic diet and prolonged fasting improve health related quality of life and blood lipid profile in multiple sclerosis - A randomized controlled trial","volume":"21","author":"Bock","year":"2015","journal-title":"Multiple Sclerosis Journal"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD004192.pub4-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"P7.253","DOI":"10.1212\/WNL.82.10_supplement.P7.253","article-title":"A double-blind placebo controlled study of the effect of beta-alanine, a nonessential amino-acid, on neurologic, motor function, quality of life, and fatigue in patients diagnosed with multiple sclerosis","volume":"82","author":"Kanter","year":"2014","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD004192.pub4-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.19082\/4899","article-title":"Effect of alpha-lipoic acid on asymmetric dimethylarginine and disability in multiple sclerosis patients: A randomized clinical trial","volume":"9","author":"Khalili","year":"2017","journal-title":"Electronic Physician"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ctim.2018.09.006","article-title":"Effects of lipoic acid on walking performance, gait, and balance in secondary progressive multiple sclerosis","volume":"41","author":"Loy","year":"2018","journal-title":"Complementary Therapies in Medicine"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0138|cit138","first-page":"287","article-title":"The role of diet in early relapsing remitting multiple sclerosis - A randomised controlled single-blind pilot study (ongoing clinical trial)","volume":"14","author":"Shah","year":"2007","journal-title":"European Journal of Neurology"},{"issue":"S16","key":"10.1002\/14651858.CD004192.pub4-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"S49.005","DOI":"10.1212\/WNL.86.16_supplement.S49.005","article-title":"Effect of MD1003 (high doses of biotin) in chronic visual loss related to optic neuritis in multiple sclerosis (MS-ON): Results of a pivotal randomized double masked placebo controlled study [abstract]","volume":"86","author":"Tourbah","year":"2016","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD004192.pub4-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40263-018-0528-2","article-title":"MD1003 (high-dose pharmaceutical-grade Biotin) for the treatment of chronic visual loss related to optic neuritis in multiple sclerosis: a randomized, double-blind, placebo-controlled study","volume":"32","author":"Tourbah","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0141|cit141","unstructured":"Dietary supplement of curcumin in subjects with active relapsing multiple sclerosis treated with subcutaneous interferon Beta 1a ClinicalTrials.gov\/show\/NCT01514370"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0142|cit142","unstructured":"Caprylic triglyceride for treatment of cognitive impairments in multiple sclerosis ClinicalTrials.gov\/show\/NCT01848327"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0143|cit143","unstructured":"Wahls Paleo diet and progressive multiple sclerosis ClinicalTrials.gov\/show\/NCT01915433"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0144|cit144","unstructured":"Personalized nutrition advice for optimizing dietary calcium intake in MS patients ClinicalTrials.gov\/show\/NCT02664623"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0145|cit145","unstructured":"Dietary approaches to treat multiple sclerosis-related fatigue study ClinicalTrials.gov\/show\/NCT02914964"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0146|cit146","unstructured":"Effect of MD1003 in progressive multiple sclerosis (SPI2) ClinicalTrials.gov\/show\/NCT02936037"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0147|cit147","unstructured":"Pilot diet study for multiple sclerosis ClinicalTrials.gov\/show\/NCT02986893"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0148|cit148","unstructured":"Low fat diet for fatigue in MS ClinicalTrials.gov\/show\/NCT03322982"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0149|cit149","unstructured":"A pilot study in subjects with relapsing remitting multiple sclerosis (RR-MS) ClinicalTrials.gov\/show\/NCT03387046"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0150|cit150","unstructured":"Nutritional approaches in multiple sclerosis ClinicalTrials.gov\/show\/NCT03508414"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0151|cit151","unstructured":"Adamczyk B Adamczyk-Sowa M New insights into the role of oxidative stress mechanisms in the pathophysiology and treatment of multiple sclerosis Oxidative medicine and cellular longevity 27829982"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0152|cit152","unstructured":"AlAmmar WA Albeesh FH Ibrahim LM Algindan YY Yamani LZ Khattab RY Effect of omega-3 fatty acids and fish oil supplementation on multiple sclerosis: a systematic review Nutritional Neuroscience 31462182"},{"issue":"3","key":"10.1002\/14651858.CD004192.pub4-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11910-017-0732-3","article-title":"Dietary interventions and multiple sclerosis","volume":"17","author":"Altowaijri","year":"2017","journal-title":"Current Neurology and Neuroscience Reports"},{"issue":"7454","key":"10.1002\/14651858.CD004192.pub4-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0155|cit155","unstructured":"Atlas of MS 2013: Mapping multiple sclerosis around the world www.msif.org\/resources"},{"issue":"3","key":"10.1002\/14651858.CD004192.pub4-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3945\/an.116.014191","article-title":"Influence of diet in multiple sclerosis: A systematic review","volume":"8","author":"Bagur","year":"2017","journal-title":"Advances in Nutrition"},{"issue":"4","key":"10.1002\/14651858.CD004192.pub4-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/ana.21939","article-title":"Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?","volume":"67","author":"Bar-Or","year":"2010","journal-title":"Annals of Neurology"},{"issue":"14","key":"10.1002\/14651858.CD004192.pub4-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1177\/1352458517691150","article-title":"Polyunsaturated fatty acids and the risk of multiple sclerosis","volume":"23","author":"Bjornevik","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"4","key":"10.1002\/14651858.CD004192.pub4-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/135245850100700409","article-title":"The brief repeatable battery of neuropsychological tests: Normative values allow application in multiple sclerosis clinical practice","volume":"7","author":"Boringa","year":"2001","journal-title":"Multiple Sclerosis"},{"issue":"1","key":"10.1002\/14651858.CD004192.pub4-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11940-003-0022-z","article-title":"Current complementary and alternative therapies for multiple sclerosis","volume":"5","author":"Bowling","year":"2003","journal-title":"Current Treatment Options in Neurology"},{"issue":"6846","key":"10.1002\/14651858.CD004192.pub4-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/bmj.305.6846.160","article-title":"Validating the SF-36 health survey questionnaire: New outcome measure for primary care","volume":"305","author":"Brazier","year":"1992","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD004192.pub4-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/jnnp-2016-314490","article-title":"Complementary and alternative treatments of multiple sclerosis: A review of the evidence from 2001 to 2016","volume":"89","author":"Claflin","year":"2018","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD004192.pub4-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S1474-4422(12)70059-5","article-title":"Disability outcome measures in multiple sclerosis clinical trials: Current status and future prospects","volume":"11","author":"Cohen","year":"2012","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0164|cit164","unstructured":"Covidence Veritas Health Innovation"},{"issue":"4","key":"10.1002\/14651858.CD004192.pub4-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ana.24747","article-title":"Long-term evolution of multiple sclerosis disability in the treatment era","volume":"80","author":"Cree","year":"2016","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.msard.2017.08.004","article-title":"Vitamin B12, folate, and homocysteine levels and multiple sclerosis: A meta-analysis","volume":"17","author":"Dardiotis","year":"2017","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0167|cit167","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"7121","key":"10.1002\/14651858.CD004192.pub4-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1136\/bmj.315.7121.1533","article-title":"Meta-analysis: Principles and procedures","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD004192.pub4-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/1028415X.2017.1303016","article-title":"The role of diet in multiple sclerosis: A review","volume":"21","author":"Esposito","year":"2018","journal-title":"Nutritional Neuroscience"},{"issue":"14","key":"10.1002\/14651858.CD004192.pub4-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa1200303","article-title":"Primary prevention of cardiovascular disease with a Mediterranean diet","volume":"368","author":"Estruch","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"S1","key":"10.1002\/14651858.CD004192.pub4-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1093\/clinids\/18.Supplement_1.S79","article-title":"Measuring the functional impact of fatigue: Initial validation of the fatigue impact scale","volume":"18","author":"Fisk","year":"1994","journal-title":"Clinical Infectious Diseases"},{"issue":"12","key":"10.1002\/14651858.CD004192.pub4-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0173|cit173","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2015"},{"issue":"3","key":"10.1002\/14651858.CD004192.pub4-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0175|cit175","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"9","key":"10.1002\/14651858.CD004192.pub4-BIB0176|cit176","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008422.pub3","article-title":"Vitamin D for the management of multiple sclerosis","author":"Jagannath","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3-4","key":"10.1002\/14651858.CD004192.pub4-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000360528","article-title":"Multiple sclerosis: Current knowledge and future outlook","volume":"72","author":"Kamm","year":"2014","journal-title":"European Neurology"},{"issue":"10","key":"10.1002\/14651858.CD004192.pub4-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","article-title":"The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus","volume":"46","author":"Krupp","year":"1989","journal-title":"Archives of Neurology"},{"issue":"11","key":"10.1002\/14651858.CD004192.pub4-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurological impairment in multiple sclerosis: An expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ctim.2009.03.001","article-title":"Complementary and alternative medicines and dietary interventions in multiple sclerosis: What is being used in South Australia and why?","volume":"17","author":"Leong","year":"2009","journal-title":"Complementary Therapies in Medicine"},{"issue":"4","key":"10.1002\/14651858.CD004192.pub4-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD004192.pub4-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD004192.pub4-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ncl.2004.09.002","article-title":"The pathology of multiple sclerosis","volume":"23","author":"Lucchinetti","year":"2005","journal-title":"Neurologic Clinics"},{"issue":"13","key":"10.1002\/14651858.CD004192.pub4-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1212\/WNL.0b013e3181d6b125","article-title":"Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis","volume":"74","author":"Marrie","year":"2010","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD004192.pub4-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/oxfordjournals.bmb.a071393","article-title":"Diagnosis and classification of multiple sclerosis","volume":"33","author":"McDonald","year":"1977","journal-title":"British Medical Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD004192.pub4-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for MS: Guidelines from the International Panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/ncpneuro1009","article-title":"Polyunsaturated fatty acids and their potential therapeutic role in multiple sclerosis","volume":"5","author":"Mehta","year":"2009","journal-title":"Nature Clinical Practice Neurology"},{"issue":"7513","key":"10.1002\/14651858.CD004192.pub4-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0140-6736(67)90850-1","article-title":"Long-term treatment of multiple sclerosis with corticotrophin","volume":"2","author":"Millar","year":"1967","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD004192.pub4-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD004192.pub4-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1179\/174313208X325038","article-title":"Examining the evidence: Complementary adjunctive therapies for multiple sclerosis","volume":"30","author":"Namaka","year":"2008","journal-title":"Neurological Research"},{"issue":"13","key":"10.1002\/14651858.CD004192.pub4-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJM200009283431307","article-title":"Multiple sclerosis","volume":"343","author":"Noseworthy","year":"2000","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00415-011-6226-3","article-title":"Patterns of dietary and herbal supplement use by multiple sclerosis patients","volume":"259","author":"O\u2019Connor","year":"2012","journal-title":"Journal of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD004192.pub4-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.1365-277X.2001.00308.x","article-title":"Nutrition and diet in the clinical management of multiple sclerosis","volume":"14","author":"Payne","year":"2001","journal-title":"Journal of Human Nutrition and Dietetics"},{"issue":"6","key":"10.1002\/14651858.CD004192.pub4-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \"McDonald Criteria\"","volume":"58","author":"Polman","year":"2005","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD004192.pub4-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Annals of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD004192.pub4-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: Guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1046\/j.1468-1331.2003.00758.x","article-title":"Why physicians need to look more closely at the use of complementary and alternative medicine by multiple sclerosis patients","volume":"11","author":"Pucci","year":"2004","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0198|cit198","unstructured":"Review Manager 5 (RevMan 5) Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"issue":"11","key":"10.1002\/14651858.CD004192.pub4-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S1474-4422(06)70598-1","article-title":"Vitamin B12, folic acid, and the nervous system","volume":"5","author":"Reynolds","year":"2006","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD004192.pub4-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1749-6632.1965.tb20235.x","article-title":"Problems of experimental trials of therapy in multiple sclerosis: Report by the panel of evaluation of experimental trials in multiple sclerosis","volume":"122","author":"Schumacher","year":"1965","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"1","key":"10.1002\/14651858.CD004192.pub4-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1191\/1352458505ms1119oa","article-title":"Multiple sclerosis and nutrition","volume":"11","author":"Schwarz","year":"2005","journal-title":"Multiple Sclerosis"},{"issue":"2","key":"10.1002\/14651858.CD004192.pub4-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0899-9007(02)00851-1","article-title":"Review of MS patient survival on a swank low saturated fat diet","volume":"19","author":"Swank","year":"2003","journal-title":"Nutrition"},{"issue":"5","key":"10.1002\/14651858.CD004192.pub4-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0899-9007(02)01099-7","article-title":"How saturated fats may be a causative factor in multiple sclerosis and other diseases","volume":"19","author":"Swank","year":"2003","journal-title":"Nutrition"},{"issue":"2","key":"10.1002\/14651858.CD004192.pub4-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurology"},{"issue":"1","key":"10.1002\/14651858.CD004192.pub4-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.acn.2005.07.006","article-title":"A comprehensive review of the Paced Auditory Serial Addition Test (PASAT)","volume":"21","author":"Tombaugh","year":"2006","journal-title":"Arch Clin Neuropsychol"},{"issue":"S1","key":"10.1002\/14651858.CD004192.pub4-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/ene.12883","article-title":"Disease-modifying treatments for multiple sclerosis - a review of approved medications","volume":"23","author":"Torkildsen","year":"2016","journal-title":"European Journal of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD004192.pub4-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ncl.2010.12.008","article-title":"Natural history of multiple sclerosis: Have available therapies impacted long-term prognosis?","volume":"29","author":"Trojano","year":"2011","journal-title":"Neurologic Clinics"},{"issue":"3","key":"10.1002\/14651858.CD004192.pub4-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF02260859","article-title":"A health-related quality of life measure for multiple sclerosis","volume":"4","author":"Vickrey","year":"1995","journal-title":"Quality of Life Research"},{"issue":"3","key":"10.1002\/14651858.CD004192.pub4-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1586\/eci.10.12","article-title":"Complementary and alternative medicine for the treatment of multiple sclerosis","volume":"6","author":"Yadav","year":"2010","journal-title":"Expert Review of Clinical Immunology"},{"issue":"12","key":"10.1002\/14651858.CD004192.pub4-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1212\/WNL.0000000000000250","article-title":"Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis","volume":"82","author":"Yadav","year":"2014","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD004192.pub4-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00415-015-7986-y","article-title":"Optimizing treatment success in multiple sclerosis","volume":"263","author":"Ziemssen","year":"2016","journal-title":"Journal of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD004192.pub4-BIB0212|cit212","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004192","article-title":"Dietary interventions for multiple sclerosis (Protocol)","author":"Farinotti","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD004192.pub4-BIB0213|cit213","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004192","article-title":"Dietary interventions for multiple sclerosis","author":"Farinotti","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD004192.pub4-BIB0214|cit214","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004192.pub3","article-title":"Dietary interventions for multiple sclerosis","author":"Farinotti","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T11:52:58Z","timestamp":1707911578000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD004192.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,5,19]]},"references-count":214,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004192.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,19]]}}}